MONARCH 1, a Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients With Refractory HR + /HER2 − Metastatic Breast Cancer
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-17-0754
Full Text
Open PDFAbstract
Available in full text
Date
May 22, 2017
Authors
Publisher
American Association for Cancer Research (AACR)